Globally, 1.7 million new cases of gastric and esophageal cancer occur each year.
1 With more than 1.3 million deaths per year, these cancers remain among the leading causes of cancer-related mortality worldwide.
1 Recurrent or metastatic disease affects about 75% of patients with esophagogastric adenocarcinomas (EGAs) at some point. For these patients, palliative systemic therapy remains the mainstay of treatment.